Vancomycin monotherapy may be insufficient to treat methicillin-resistant staphylococcus aureus coinfection in children with influenza-related critical illness

Clinical Infectious Diseases

Volumn 68, Issue 3, 2019, Pages 365-372

  Randolph, Adrienne G ^a,b   Xu, Ruifei ^a   Novak, Tanya ^a   Newhams, Margaret M ^a   Wardenburg, Juliane Bubeck ^c   Weiss, Scott L ^d   Sanders, Ronald C ^e   Thomas, Neal J ^f   Hall, Mark W ^g   Tarquinio, Keiko M ^h   Cvijanovich, Natalie ⁱ   Gedeit, Rainer G ^j   Truemper, Edward J ^k   Markovitz, Barry ^l   Hartman, Mary E ^c   Ackerman, Kate G ^m   Giuliano, John S ⁿ   Shein, Steven L ^o   Moffitt, Kristin L ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c ST LOUIS CHILDREN S HOSPITAL   (United States)

^d CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^e ARKANSAS CHILDREN S HOSPITAL   (United States)

^f PENN STATE CHILDREN S HOSPITAL   (United States)

^g NATIONWIDE CHILDREN S HOSPITAL   (United States)

^h EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ CHILDREN S HOSPITAL OAKLAND   (United States)

^j Children's Hospital of Wisconsin   (United States)

^k UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^l CHILDREN S HOSPITAL LOS ANGELES   (United States)

^m UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

ⁿ YALE NEW HAVEN CHILDREN S HOSPITAL   (United States)

^o CASE WESTERN RESERVE UNIVERSITY   (United States)

more..

Author keywords

children; influenza; methicillin resistant Staphylococcus aureus; mortality.; vancomycin

Indexed keywords

CEFTAROLINE; CLINDAMYCIN; DOPAMINE; EPINEPHRINE; GRANULOCYTE COLONY STIMULATING FACTOR; HYPERTENSIVE FACTOR; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; LINEZOLID; NORADRENALIN; OSELTAMIVIR; PHENYLEPHRINE; TUMOR NECROSIS FACTOR; VANCOMYCIN; ANTIINFECTIVE AGENT;

ACUTE LUNG INJURY; ANTIBIOTIC THERAPY; ARTICLE; ARTIFICIAL VENTILATION; CHILD; CLINICAL OUTCOME; CRITICAL ILLNESS; DRUG USE; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACORPOREAL OXYGENATION; FEMALE; HOSPITALIZATION; HUMAN; INFLUENZA; INFLUENZA A; INFLUENZA B; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MIXED INFECTION; MONOTHERAPY; MORTALITY; PRIORITY JOURNAL; RESPIRATORY DISTRESS SYNDROME; RESPIRATORY FAILURE; STAPHYLOCOCCAL PNEUMONIA; ADOLESCENT; COMPLICATION; INFANT; ISOLATION AND PURIFICATION; MICROBIOLOGY; NEWBORN; PATHOLOGY; PRESCHOOL CHILD; PROSPECTIVE STUDY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

ADOLESCENT; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; COINFECTION; CRITICAL ILLNESS; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; INFLUENZA, HUMAN; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; PNEUMONIA, STAPHYLOCOCCAL; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VANCOMYCIN;

EID: 85060176384     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciy495     Document Type: Article

References (39)

1. Reed C, Kallen AJ, Patton M, et al. Infection with community-onset Staphylococcus aureus and influenza virus in hospitalized children. Pediatr Infect Dis J 2009; 28:572-6.
2. Centers for Disease Control and Prevention. Severe methicillin-resistant Staphylococcus aureus community-acquired pneumonia associated with influenza- Louisiana and Georgia, December 2006-January 2007. MMWR Morb Mortal Wkly Rep 2007; 56:325-9.
3. Finelli L, Fiore A, Dhara R, et al. Influenza-associated pediatric mortality in the United States: Increase of Staphylococcus aureus coinfection. Pediatrics 2008; 122:805-11.
4. Rice TW, Rubinson L, Uyeki TM, et al. Critical illness from 2009 pandemic influenza A virus and bacterial coinfection in the United States. Crit Care Med 2012; 40:1487-98.
5. Randolph AG, Vaughn F, Sullivan R, et al. Critically ill children during the 2009-2010 influenza pandemic in the United States. Pediatrics 2011; 128:e1450-8.
6. Bradley JS, Byington CL, Shah SS, et al; Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. The management of community-acquired pneumonia in infants and children older than 3 months of age: Clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis 2011; 53:e25-76.
7. Deresinski S. Vancomycin in combination with other antibiotics for the treatment of serious methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2009; 49:1072-9.
8. Chiang FY, Climo M. Efficacy of linezolid alone or in combination with vancomycin for treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47:3002-4.
9. Jacqueline C, Caillon J, Le Mabecque V, et al. In vitro activity of linezolid alone and in combination with gentamicin, vancomycin or rifampicin against methicillin-resistant Staphylococcus aureus by time-kill curve methods. J Antimicrob Chemother 2003; 51:857-64.
10. Bubeck Wardenburg J, Patel RJ, Schneewind O. Surface proteins and exotoxins are required for the pathogenesis of Staphylococcus aureus pneumonia. Infect Immun 2007; 75:1040-4.
11. Ragle BE, Bubeck Wardenburg J. Anti-alpha-hemolysin monoclonal antibodies mediate protection against Staphylococcus aureus pneumonia. Infect Immun 2009; 77:2712-8.
12. Kobayashi SD, Malachowa N, Whitney AR, et al. Comparative analysis of USA300 virulence determinants in a rabbit model of skin and soft tissue infection. J Infect Dis 2011; 204:937-41.
13. Berube BJ, Bubeck Wardenburg J. Staphylococcus aureus α-toxin: nearly a century of intrigue. Toxins (Basel) 2013; 5:1140-66.
14. Yu KO, Randolph AG, Agan AA, et al; Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) PICFlu Study Group. Staphylococcus aureus α-toxin response distinguishes respiratory virus-methicillin-resistant S. aureus coinfection in children. J Infect Dis 2016; 214:1638-46.
15. Loffler B, Niemann S, Ehrhardt C, et al. Pathogenesis of Staphylococcus aureus necrotizing pneumonia: The role of PVL and an influenza coinfection. Expert Rev Anti Infect Ther 2013; 11:1041-51.
16. Cardot Martin E, Michel A, Raynal B, et al. Community-acquired meticillin-resistant Staphylococcus aureus strain USA300 resists staphylococcal protein A modulation by antibiotics and antimicrobial peptides. Int J Antimicrob Agents 2015; 45:19-24.
17. Dumitrescu O, Badiou C, Bes M, et al. Effect of antibiotics, alone and in combination, on Panton-Valentine leukocidin production by a Staphylococcus aureus reference strain. Clin Microbiol Infect 2008; 14:384-8.
18. Otto MP, Martin E, Badiou C, et al. Effects of subinhibitory concentrations of antibiotics on virulence factor expression by community-acquired methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 2013; 68:1524-32.
19. Stevens DL, Ma Y, Salmi DB, McIndoo E, Wallace RJ, Bryant AE. Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus. J Infect Dis 2007; 195:202-11.
20. Berger ML, Sox H, Willke RJ, et al. Good practices for real-world data studies of treatment and/or comparative effectiveness: Recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making. Pharmacoepidemiol Drug Saf 2017; 26:1033-9.
21. Hall MW, Geyer SM, Guo CY, et al; Pediatric Acute Lung Injury and Sepsis Investigators Network PICFlu Study Investigators. Innate immune function and mortality in critically ill children with influenza: A multicenter study. Crit Care Med 2013; 41:224-36.
22. Fiore-Gartland A, Panoskaltsis-Mortari A, Agan AA, et al; PALISI PICFlu Investigators. Cytokine profiles of severe influenza virus-related complications in children. Front Immunol 2017; 8:1423.
23. Randolph AG, Yip WK, Allen EK, et al. Evaluation of IFITM3 rs12252 association with severe pediatric influenza infection. J Infect Dis 2017; 216:14-21.
24. Kroger AT, Atkinson WL, Marcuse EK, Pickering LK; Advisory Committee on Immunization Practices Centers for Disease Control and Prevention. General recommendations on immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006; 55:1-48.
25. Centers for Disease Control and Prevention. Official CDC Health Advisory: Influenza-associated pediatric mortality and Staphylococcus aureus co-infection. Atlanta, GA: Department of Health and Human Services (US); 2008:1-2.
26. Ferdinands JM, Olsho LE, Agan AA, et al. Effectiveness of influenza vaccine against life-threatening RT-PCR-confirmed influenza illness in US children, 2010-2012. J Infect Dis 2014; 210:674-83.
27. Pierce VM, Hodinka RL. Comparison of the GenMark Diagnostics eSensor respiratory viral panel to real-time PCR for detection of respiratory viruses in children. J Clin Microbiol 2012; 50:3458-65.
28. Pollack MM, Patel KM, Ruttimann UE. PRISM III: An updated pediatric risk of mortality score. Crit Care Med 1996; 24:743-52.
29. Bernard GR, Artigas A, Brigham KL, et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994; 149:818-24.
30. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009; 42:377-81.
31. Frymoyer A, Hersh AL, Benet LZ, Guglielmo BJ. Current recommended dosing of vancomycin for children with invasive methicillin-resistant Staphylococcus aureus infections is inadequate. Pediatr Infect Dis J 2009; 28:398-402.
32. Durham SH, Simmons ML, Mulherin DW, Foland JA. An evaluation of vancomycin dosing for complicated infections in pediatric patients. Hosp Pediatr 2015; 5:276-81.
33. Demirjian A, Finkelstein Y, Nava-Ocampo A, et al. A randomized controlled trial of a vancomycin loading dose in children. Pediatr Infect Dis J 2013; 32:1217-23.
34. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: Executive summary. Clin Infect Dis 2011; 52:285-92.
35. Jeffres MN, Isakow W, Doherty JA, et al. Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: Specific evaluation of vancomycin pharmacokinetic indices. Chest 2006; 130:947-55.
36. Stein GE, Wells EM. The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus: Vancomycin and linezolid. Curr Med Res Opin 2010; 26:571-88.
37. Sutter DE, Milburn E, Chukwuma U, Dzialowy N, Maranich AM, Hospenthal DR. Changing susceptibility of Staphylococcus aureus in a US pediatric population. Pediatrics 2016; 137:e20153099.
38. Hodille E, Rose W, Diep BA, Goutelle S, Lina G, Dumitrescu O. The role of antibiotics in modulating virulence in Staphylococcus aureus. Clin Microbiol Rev 2017; 30:887-917.
39. Cies JJ, Moore WS, 2nd, Enache A, Chopra A. Ceftaroline for suspected of confirmed invasive methicillin-resistant Staphylococcus aureus: A pharmacokinetic case series. Pediatr Crit Care Med 2018; 19:e292-9.